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Trigger Cell Types/Lines Molecular Mechanism Chemical Inhibitors
TNF + caspase-8 inhibition (by 
pan-caspase inhibitor zVAD, 
caspase-8 inhibitor IETD, 
caspase-8 knockdown or 
knockout, overexpression of 
viral protein CrmA)
MEF, L929, Jurkat, NIH3T3 The stimulation of TNFR1 by TNF leads to the formation of a transient 
complex associated with the intracellular domain of TNFR1, named 
complex I, where RIP1 is ubiquitinated by cIAP1/2 and LUBAC. After 
the dissociation of complex I, RIP1 interacts with RIP3 to form an 
intracellular amyloid-like complex named complex IIb or necrosome 
in a RIP1-kinase-dependent manner. Deubiquitination of RIP1 by 
CYLD promotes the formation of complex IIb. Oligomerization of RIP1 
and RIP3 leads to MLKL phosphorylation by RIP3, which is required 
for MLKL trimerization and translocation to plasma membrane, 
resulting in Ca2+ and/or Na+ influx as one of the final execution steps 
of necroptosis. Necroptosis can be sensitized by inhibitor of protein 
translation CHX, which suppresses the synthesis of survival factors.
RIP1 kinase inhibitors necrostatin-1, 3, 4, 5; 
RIP3 kinase inhibitors GSK’843, GSK’872; 
MLKL inhibitor necrosulfonamide; Ca2+ 
chelator BAPTA-AM
TNF L929, FADD-deficient Jurkat These cells are defective in caspase-8 activation in response to TNF so 
they can undergo necroptosis without caspase inhibition.
Necrostatin-1, 3, 4, 5
FAS ligand + caspase-8 
inhibition (by zVAD or caspase-8 
knockout)
PHA/IL-2-activated human CD4+ T 
cells, ConA/IL-2-activated murine 
splenic T cells, Jurkat, CCRF-CEM 
RIP1 kinase activity is required for the cell death. Necrostatin-1
Fas ligand + IAP antagonist 
+ zVAD
HaCaT The cell death is dependent on RIP1 kinase activity and is protected 
by cFLIPL overexpression. TWEAK, which promotes the degradation 
of cIAP1, can sensitize cells to Fas-ligand-induced cell death with a 
similar mechanism.
Necrostatin-1
TCR engagement + caspase-8 
inhibition (by zVAD, caspase-8 
knockout, or FADD death 
domain overexpression)
Murine CD4+ T cells, murine CD8+ 
T cells, human peripheral blood 
lymphocytes
Activation-induced cell death (AICD) of mature T cells is mediated 
by the induction of Fas ligand. Failure to activate caspase-8 due 
to chemical inhibition or genetic deficiency of caspase-8 or FADD 
predisposes T cells to necroptosis in response to the Fas ligand 
induced by TCR signaling. RIP1 kinase activity and RIP3 are required 
for the cell death.
Necrostatin-1
TRAIL in acidic condition HT-29, MEF, HepG2 RIP1 kinase activity, RIP3, and PARP-1 polymerase activity are required 
for the cell death.
Necrostatin-1, PARP-1 inhibitor PJ-34
TRAIL + zVAD Jurkat, HaCaT, U937, Mz-ChA-1, 
BxPC-3, HT-29
The cell death is sensitized by IAP antagonist or by protein synthesis 
inhibitor CHX. RIP1 kinase activity is required for the cell death.
Necrostatin-1
TNF + cIAP1/2 depletion (by IAP 
antagonist or cIAP1 knockout) 
+ zVAD
MEF, MDF, Panc-1, Jurkat, U937, 
CCRF-CEM, L929, macrophage
This combination treatment induces the interaction of RIP1 kinase and 
RIP3 to form the complex IIb. RIP1 was detected in a complex of ~2 
MDa which contains additional components such as caspase-8 and 
FADD.
Necrostatin-1
LTα + IAP antagonist + pan-
caspase inhibitor QVD
MDF LTα homotrimer binds to TNFR1 and leads to TNFR1 signaling in a 
similar way to TNF-induced necroptosis.
Necrostatin-1
IAP antagonist + zVAD HT-29, MDA-MB-231, SKOV3, Kym-1, 
macrophage
The cell death is dependent on RIP1 kinase activity. Interaction 
between RIP1 and caspase-8 was detected in a complex of ~2 MDa.
Necrostatin-1
TNF + TAK1 inhibitor 5z-7 or 
TAK knockdown + zVAD
L929, MEF The formation of complex I associated with TNFR1 is not affected by 
TAK1 inhibition, whereas the formation of necrosome (complex IIb) is 
facilitated by TAK1 inhibition. RIP1 kinase activity is required for the 
formation of necrosome.
Necrostatin-1
TLR2, TLR5, or TLR9 agonist 
+ zVAD
Macrophage, microglia The autocrine production of TNF, which is induced by TLR signaling, 
leads to necroptosis in the absence of caspase-8 activity.
Necrostatin-1
Poly(I:C) agonist + zVAD Macrophage, microglia RIP1, RIP3, and TRIF form necrosome independently of autocrine TNF. 
RIP1 kinase activity, RIP3, TRIF, but not IRF3, are required for the cell 
death.
Necrostatin-1, RIP3 kinase inhibitor GSK’843, 
GSK’872
LPS + zVAD Macrophage, microglia Both autocrine production of TNF and RIP1-RIP3-TRIF axis contribute 
to the cell death.
Necrostatin-1
Poly(I:C) + IAP antagonist + 
zVAD
HaCaT, MET-1 The cell death requires RIP1 kinase activity and RIP3 and is negatively 
regulated by cFLIP. RIP1 is detected in a ~2 MDa complex named 
ripoptosome, which also includes cFLIPS and caspase-8. Ripoptosome 
forms independently of TNF signaling.
Necrostatin-1
Poly(I:C) GM-CSF-induced BMDC The cell death is dependent on RLR adaptor MAVS/IPS-1/VISA/
Cardif and the release of lysosomal cathepsin D which in turn cleaves 
caspase-8. RIP1 kinase activity and RIP3 are required for the cell death.
Cathepsin D inhibitor pepstatin A;  
Necrostatin-1
IFNα/β Primary FADD–/– MEF at subconfluency PKR is transcriptionally upregulated by Type I interferon. The cell death 
requires the kinase activities of JAK, PKR, and RIP1.
JAK kinase inhibitor I; PKR inhibitor C16 and 
2-aminopurine; Necrostatin-1
IFNγ Primary FADD–/– MEF at subconfluency, 
RelA–/– MEF, J774A.1
PKR is transcriptionally upregulated by IFNγ. The activation of JAK-
STAT1 axis by IFNγ triggers the formation of necrosome consisting of 
RIP1, RIP3, and PKR. JAK, PKR, and RIP3 are required for cell death. 
RIP1 kinase inhibition reduces the cell death but does not significantly 
affect the formation of necrosome.
RNA polymerase II inhibitor Actinomycin D; 
JAK kinase inhibitor I; PKR inhibitor C16 and 
2-aminopurine; Necrostatin-1
Oxygen glucose deprivation Retinal ganglion cells (RGC) Oxygen glucose deprivation (OGD), an in vitro condition mimicking 
ischemic injury, promotes cell death predominantly by necrosis. The 
necrosis is dependent on RIP1 kinase.
Necrostatin-1
Glutamate, NMDA HT-22, primary rat cortical cells Excitotoxicity in neurons is mediated by mitochondrial oxidative stress 
and MAPK activation and is dependent on RIP1 kinase.
ROS scavenger N-acetyl-cysteine, 
Necrostatin-1
Salmonella enterica serovar 
Typhimurium
Macrophage Type I interferon is required for the cell death, but not inflammasome 
activation and cytokine secretion. RIP1 is recruited to IFNAR1, leading 
to necroptosis mediated by RIP1 kinase and RIP3. Caspase-1 also 
contributes to the cell death.
Necrostatin-1; caspase-1 inhibitor YVAD-CHO
Murine cytomegalovirus (CMV) 
M45mutRHIM
SVEC4-10, 3T3-Swiss albino, MEF CMV infection induces DAI interaction with RIP3, leading to RIP3-
dependent necroptosis without the requirement for RIP1 kinase. CMV 
M45-encoded vIRA abrogates DAI-RIP3 interaction. Therefore, CMV 
can infect cells without causing cell death unless its vIRA is disrupted 
by mutation.
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Necroptosis is a form of regulated necrotic cell death mediated by RIP1 kinase and RIP3. Necroptosis is characterized by early loss of plasma membrane integrity, leakage of 
intracellular contents, and organelle swelling. The cells dying through necroptosis lack the typical apoptotic characteristics, such as membrane blebbing, chromatin condensa-
tion, and intranucleosomal DNA cleavage into 180 bp DNA laddering, but may show TUNEL positivity.
The establishment of necroptosis as a form of regulated necrotic cell death overturned the traditional belief that necrosis could only be a passive process caused by 
overwhelming stress. Necroptosis can be triggered by extracellular stimuli known to activate inflammation and cell death as summarized in the table. RIP1 kinase, a key upstream 
regulator of the pathway, is modulated intricately by multiple phosphorylation and ubiquitination events, which dictate the cellular fate to life or death. The intracellular signaling 
pathway of necroptosis involves the formation of complex IIb or necrosome, wherein RIP1 kinase binds and activates RIP3. The execution step of necroptosis involves the 
activation of pseudokinase MLKL by phosphorylation, resulting in MLKL translocation to the plasma and cytoplasmic membranes where it modulates ion channel activities to 
lead to necrosis.
Inhibition of necroptosis has been shown to mitigate pathology in mouse models of numerous diseases involving cell death and inflammation, such as acute ischemia-
reperfusion injury in the brain, heart, retina, and kidney; traumatic brain injury; age-related macular degeneration; atherosclerosis; inflammatory bowel disease; Gaucher’s 
disease; and allograft rejection. Inhibition of necroptosis might provide benefits to the treatment of multiple human diseases involving inflammation and cell death.
Abbreviations
TNF, tumor necrosis factor alpha; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling; PI, propidium iodide; RIP1, receptor-interacting protein 1; CHX, 
cycloheximide; cIAP, inhibitor of apoptosis protein; CYLD, cylindromatosis; RIP3, receptor-interacting protein 3; MLKL, mixed lineage kinase domain-kike; FADD, FAS-associating 
death domain-containing protein; PHA, phytohemagglutinin; IL-2, interleukin 2; ConA, concanavalin A; TCR, T cell receptor; TRAIL, TNF-related apoptosis-inducing ligand; LTα, 
lymphotoxin alpha; TAK1, transforming growth factor-beta-activated kinase 1; TLR, toll-like receptor; TRIF, TIR-domain-containing adaptor-inducing interferon-beta, also named 
TICAM-1, TIR domain-containing adaptor molecule 1; PKR, interferon-induced, double-stranded RNA-activated protein kinase, also named EIF2AK2, eukaryotic translation 
initiation factor 2-alpha kinase 2; vIRA, viral inhibitor of RIP activation.
RefeRenCes
Christofferson, D.E., Li, Y., and Yuan, J. (2014). Annu. Rev. Physiol. 76, 129–150.
Du, Q., Xie, J., Kim, H.-J., and Ma, X. (2013). Cell. Mol. Immunol. 10, 4–6.
Mocarski, E.S., Upton, J.W., and Kaiser, W.J. (2012). Nat. Rev. Immunol. 12, 79–88.
Ofengeim, D., and Yuan, J. (2013). Nat. Rev. Mol. Cell Biol. 14, 727–736.
Zhou, Z., Han, V., and Han, J. (2012). Protein Cell 3, 811–817.
